Also news on MSB plans for Europe,
From the Q4 2018 Earnings call Q4 2018
Dr. Silviu Itescu
Sure, as you know, Europe has similar but not necessarily the same regulatory environment as the U.S. for regenerative medicine and we’ve had multiple discussions with EMA prior to initiating this study. We will be coming back and having discussions of EMA in parallel with the FDA and we will be presenting not just EAP data, which previously was well known to European agencies but now this new pediatric data. And we would expect to fully outline to the market over the next couple of months European strategy.
Also news on MSB plans for Europe, From the Q4 2018 Earnings...
-
- There are more pages in this discussion • 1,432 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |